Adenosine Phosphate

Summary

Adenosine Phosphate (CHEMBL752) is an approved small-molecule EC 3.1.3.11 (fructose-bisphosphatase) inhibitor targeting TRPM4; indicated across 1 condition including ischemic disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Targets: 1 (TRPM4)
• Indications: 1 condition
• Clinical trials: 7
• Chemistry: 347.22 Da · C10H14N5O7P

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL752
Name	Adenosine Phosphate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	6083
ChEBI	CHEBI:16027
Molecular formula	C10H14N5O7P
Molecular weight	347.22
InChIKey	UDMBCSSLTHHNCD-KQYNXXCUSA-N

SMILES: C1=NC(=C2C(=N1)N(C=N2)[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)N

IUPAC name: [(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate

ChEBI definition: A purine ribonucleoside 5’-monophosphate having adenine as the nucleobase.

Pharmacological roles (ChEBI): EC 3.1.3.11 (fructose-bisphosphatase) inhibitor, EC 3.1.3.1 (alkaline phosphatase) inhibitor, adenosine A1 receptor agonist, nutraceutical, micronutrient, cofactor.

Other ChEBI roles (chemical / environmental): fundamental metabolite.

Also known as: 5’-adenylic acid, A 5MP, A-5MP, Adenosine 5’-monophosphoric acid, Adenosine phosphate, Adenyl, Adenosine monophosphate (amp), Fosfato de adenosina, NSC-20264, Phosphate d’adenosine, Vitamin b8, AMP

Parent form; salt/anhydrous children: CHEMBL1315633, CHEMBL1627080

Patent coverage: 64,452 distinct patent families (165,316 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 162,307 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
	AMP kinase	Activation	4.21
TRPM4	TRPM4	Antagonist	4.7	0.5%	Q8TD43

Broader ChEMBL bioactivity targets: 25 (assay-derived). Sample: Transient receptor potential cation channel subfamily M member 2, Survival motor neuron protein, AMP-activated protein kinase, AMPK, Beta-2 adrenergic receptor, AMP-activated protein kinase (AMPK) alpha-1/beta-1/gamma-1, Alcohol dehydrogenase, Adenosine receptor A1, Fructose-1,6-bisphosphatase 1, Adenylate kinase 2, mitochondrial, Voltage-gated inwardly rectifying potassium channel KCNH2.

Bioactivity

ChEMBL activities: 30 potent at pChembl ≥ 5 of 46 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P2RY2	7.07	EC50	85	nM	CHEMBL_ACT_469050
SRC	7	IC50	100	nM	CHEMBL_ACT_2202567
FBP1	6.85	IC50	140	nM	CHEMBL_ACT_3081751
PRKAB2	6.82	Kd	150	nM	CHEMBL_ACT_25864839
FBP1	6.36	IC50	440	nM	CHEMBL_ACT_3081750
ADORA1	6.3	EC50	500	nM	CHEMBL_ACT_12089148
FBP1	6.1	IC50	800	nM	CHEMBL_ACT_262809
FBP1	6	IC50	1000	nM	CHEMBL_ACT_14537971
FBP1	6	IC50	1000	nM	CHEMBL_ACT_2508938
FBP1	6	IC50	1000	nM	CHEMBL_ACT_25106488
P00636	5.89	IC50	1300	nM	CHEMBL_ACT_2655867
P00636	5.89	IC50	1300	nM	CHEMBL_ACT_3268095
PRKAG1	5.85	EC50	1400	nM	CHEMBL_ACT_20599865
PRKAG1	5.82	EC50	1519	nM	CHEMBL_ACT_16667857
P2RY1	5.82	EC50	1500	nM	CHEMBL_ACT_469049
Q27757	5.7	Potency	1995	nM	CHEMBL_ACT_3956789
FBP1	5.64	IC50	2300	nM	CHEMBL_ACT_18891765
FBP1	5.64	IC50	2300	nM	CHEMBL_ACT_22788103
FBP1	5.58	IC50	2600	nM	CHEMBL_ACT_20713205
P49652	5.55	EC50	2800	nM	CHEMBL_ACT_469048
FBP1	5.5	IC50	3200	nM	CHEMBL_ACT_13955146
FBP1	5.5	IC50	3200	nM	CHEMBL_ACT_15148225
FBP1	5.48	IC50	3300	nM	CHEMBL_ACT_22891722
P49652	5.46	EC50	3500	nM	CHEMBL_ACT_448106
PRKAG1	5.43	Kd	3700	nM	CHEMBL_ACT_16667872
P2RY2	5.43	EC50	3700	nM	CHEMBL_ACT_448108
PRKAB2	5.23	EC50	5900	nM	CHEMBL_ACT_5293839
P2RY1	5.14	EC50	7200	nM	CHEMBL_ACT_448107
ADRB2	5.02	AC50	9500	nM	CHEMBL_ACT_25233811
FBP1	5.01	IC50	9800	nM	CHEMBL_ACT_3268096

Target pathways

Aggregated over 1 target gene(s): TRPM4.

Top Reactome pathways

2 total, by targets touching each:

Pathway	Targets	Genes
TRP channels	1	TRPM4
Sensory perception of sweet, bitter, and umami (glutamate) taste	1	TRPM4

Dominant GO biological processes

GO term	Targets
adaptive immune response	1
dendritic cell chemotaxis	1
regulation of T cell cytokine production	1
positive regulation of cytosolic calcium ion concentration	1
positive regulation of cell population proliferation	1
positive regulation of heart rate	1
protein sumoylation	1
calcium-mediated signaling	1
metal ion transport	1
negative regulation of bone mineralization	1
positive regulation of insulin secretion involved in cellular response to glucose stimulus	1
positive regulation of fat cell differentiation	1
negative regulation of osteoblast differentiation	1
positive regulation of vasoconstriction	1
protein homotetramerization	1

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
ischemic disease	1	MONDO:0005053	EFO:0000556

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
Not specified	3
PHASE4	2
PHASE2	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00483795	PHASE4	COMPLETED	Pilot Evaluation of Two Multipurpose Solutions in Regards to Corneal Staining
NCT02574975	PHASE4	UNKNOWN	Assessment of Airway Responsiveness and Treatment Efficacy in Asthmatics
NCT01173887	PHASE2	COMPLETED	Multicenter, Randomized, Open-label, Parallel-group Study to Compare mLSG15 + KW-0761 to mLSG15
NCT03738943	EARLY_PHASE1	COMPLETED	Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults
NCT00602563	Not specified	COMPLETED	Attention Training for Generalized Anxiety Disorder
NCT02485158	Not specified	COMPLETED	Individual Differences in the Response to Drugs
NCT06181916	Not specified	UNKNOWN	Quantitative and Qualitative Research for mHealth Program to Support People Living With HIV Across the HIV Care Continuum

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).